HOME >> MEDICINE >> NEWS
Discovery may prevent life-threatening wasting disease in patients with chronic kidney disease

Researchers at Oregon Health & Science University's Doernbecher Children's Hospital have uncovered a unique therapeutic strategy to combat cachexia -- severe malnutrition and physical wasting away -- in children and adults with chronic kidney disease (CKD). The study is published in the June issue of the Journal of Clinical Investigation.

Although the exact cause of cachexia -- a common life-threatening complication of CKD, cancer, AIDS and heart failure patients -- is unknown, Doernbecher researchers found elevated levels of leptin, a hormone that is produced by fat cells and plays a role in weight regulation, may be the cause. Leptin signals through the hypothalamic melanocortin 4 receptor (MC4-R) pathway in the brain, and blocking this pathway may be an important avenue for treatment, they report. The study was conducted in mice.

"Understanding why patients develop cachexia is important because it is associated with very high mortality in patients with chronic kidney disease," said study investigator Robert Mak, M.D., professor of pediatrics in the OHSU School of Medicine and head of pediatric nephrology, Doernbecher Children's Hospital. "Through this research, we have found a novel therapeutic strategy to combat this life-threatening complication of chronic renal disease, which affects more than 10 percent of the population and costs $40 billion each year to treat."

In an accompanying editorial commentary, William Mitch, M.D., past president of the American Society of Nephrology and Edward Randall Distinguished Chairman in Medicine, University of Texas Medical Branch, wrote that this study "provides a quantum increase in our understanding of CKD-associated anorexia."


'"/>

Contact: Tamara Hargens
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
9-Jun-2005


Page: 1

Related medicine news :

1. Discovery of cellular processes which regulate hearts energy supply
2. Discovery in Bubble Boy disease gene therapy
3. Discovery of T-cell traffic control boosts new drug promise
4. Mayo collaboration: Discovery blocks breast cancer growth, stimulates immunity
5. Discovery of a drug anticipation brain signal
6. Discovery of key inflammation mechanism in COPD could lead to new treatments
7. Discovery of a molecular switch could lead to new ways of treating infection, including MRSA
8. Using MRI for diagnosis could help prevent breast cancer progression
9. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
10. Bioengineering to prevent iron deficiency?
11. Should adult male circumcision be recommended for HIV prevention in the US?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 2016 , ... 10 Best Water is excited to announce a ... owners that topped the list as a result of their commitment to offering clients ... was Tibet 5100, a top notch water company that specializes in providing the public ...
(Date:2/10/2016)... ... February 10, 2016 , ... United ... Nesbitt as the latest addition to its growing list of Partner Firms. ... the Southeast, from Orlando to Huntsville and in between. , Harnessing the experience ...
(Date:2/10/2016)... Boston, Massachusetts (PRWEB) , ... February 10, 2016 ... ... practice models to effectively measure change in their patients. Research shows that the ... traditional methods. To help therapists overcome this challenge and learn more about the ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX ... accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless ... the integrity of biological samples while operating at ultra-high pressures of 20,000 psi. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over ... of Medicare Part D a decade ago, according to The Senior Citizens League ... on how they are coping with rapidly rising costs. “The implications are chilling, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Astellas Pharma Inc. (TSE: ... announced today that it has successfully completed, through its ... offer to purchase all issued and outstanding shares of ... and CEO: Paul Wotton , "Ocata") for a ... in cash ("Tender Offer"). Astellas commenced the Tender Offer ...
(Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences ... and Life Sciences Report 2016 . --> ... Healthcare and Life Sciences Report 2016 . ... territory in the world for pharma manufacturing, a territory with ... and more universities per square mile than anywhere else on ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology:
Cached News: